<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Adult Burkitt-type <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) and <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>) are rare entities composing 1% to 5% of non-Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo> NHL) or ALL </plain></SENT>
<SENT sid="1" pm="."><plain>Prognosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> has been poor with conventional NHL or ALL regimens, but has improved with dose-intensive regimens </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: To evaluate the addition of rituximab, a CD20 monoclonal antibody, to intensive chemotherapy in adults with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> or <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>, 31 patients with newly diagnosed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> or <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> received the hyper-fractionated <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, and <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> (hyper-CVAD) regimen with rituximab </plain></SENT>
<SENT sid="3" pm="."><plain>Their median age was 46 years; 29% were 60 years or older </plain></SENT>
<SENT sid="4" pm="."><plain>Rituximab 375 mg/m(2) was given on Days 1 and 11 of hyper-CVAD courses and on Days 1 and 8 of <z:chebi fb="0" ids="44185">methotrexate</z:chebi> and <z:chebi fb="0" ids="28680">cytarabine</z:chebi> courses </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Complete remission (complete response [CR]) was achieved in 24 of 28 (86%) evaluable patients; 3 had a partial response, and 1 had resistant disease </plain></SENT>
<SENT sid="6" pm="."><plain>There were no induction <z:hpo ids='HP_0011420'>deaths</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>The 3-year overall survival (OS), event-free survival, and disease-free survival rates were 89%, 80%, and 88%, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>Nine elderly patients achieved CR with <z:hpo ids='HP_0000001'>all</z:hpo> of them in continuous CR (except 1 <z:hpo ids='HP_0011420'>death</z:hpo> in CR from <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>), with a 3-year OS rate of 89% </plain></SENT>
<SENT sid="9" pm="."><plain>Multivariate analysis of current and historical (those treated with hyper-CVAD alone) groups identified age and treatment with rituximab as favorable factors </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: The addition of rituximab to hyper-CVAD may improve outcome in adult <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> or <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>, particularly in elderly patients </plain></SENT>
</text></document>